IMMUNOCORE HOLDINGS PLC (IMCR)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$36.13-3.83%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Intact: The reason to own it still holds.
Immunocore is growing revenue from $75M in 2024-Q2 to $107M in 2026-Q1. Net income improved from -$30M to $13M in the same period. Cash flow from operations is also improving, down from -$33M to -$14M. The success of KIMMTRAK supports future growth.
The company is still loss-making and cash flow is negative. Earnings estimates show a possible loss next year. Key executives have left recently. Revenue guidance is missing, adding uncertainty.
The market expects about 12% revenue growth next year. Our fair value is near $96, suggesting the stock is fairly priced. We see risk if growth or profits do not improve.
Breaks if: Cash flow from operations falls below -$30M after 2026-Q1
Improve operating cash flow to support business sustainability and growth investments.
Stated as a priority in 2 of last 2 quarters. Cash, cash equivalents and marketable securities increased from $845 million in 2026-Q1 to $880 million in 2026-Q2, indicating positive cash flow management. The trajectory is delivering improvement in liquidity.
“Cash, cash equivalents and marketable securities were $880 million as of June 30, 2026”
“Cash, cash equivalents and marketable securities were $845 million as of March 31, 2026”
Breaks if: Net income falls below zero for two consecutive quarters after 2026-Q1
Focus on improving profitability, moving from net losses to net income through revenue growth and expense management.
Stated as a priority in 2 of last 2 quarters. Net income improved from losses of $10.3 million in 2025-Q2 and $5.0 million in 2025-Q1 to a net loss of $0.8 million in 2026-Q2 and net income of $13.0 million in 2026-Q1. The trajectory shows delivering progress toward profitability.
“Net loss for Q2 2026 was $0.8 million compared to $10.3 million loss for Q2 2025”
“Net income for Q1 2026 was $13.0 million compared to $5.0 million for Q1 2025”
Breaks if: Revenue falls below $75M in any quarter after 2026-Q1
Focus on increasing revenue through strategic initiatives and market expansion.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. IMCR is currently navigating a transition towards profitability while expanding its product offerings, particularly KIMMTRAK, which has shown strong sales growth.
The current valuation appears expensive compared to peers, suggesting that the market has high expectations for future performance. There is an expectations gap indicating that the market may not fully reflect the potential for revenue growth and operational improvements.
Management is focused on increasing revenue and achieving positive net income, with recent financial performance indicating progress. However, near-term risks remain elevated, particularly due to the potential for economic downturns affecting the healthcare sector.
The long-term thesis hinges on management's ability to execute on their growth plans and the overall health of the economy. Key factors include guidance updates in upcoming earnings calls and performance of sector leaders that could influence market sentiment.
Over the next 1 to 3 years, IMCR's trajectory will depend on its ability to maintain growth and navigate economic challenges. Not investment advice.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. Strong first-half profits support the expansion of KIMMTRAK. This expansion is expected to drive revenue growth for the company. There are no new threats impacting the thesis.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.